lung illness Archives - Amazing Health Advances

Study looks at Lung Injury and Vaping THC and Vitamin E Acetate

AHA Publisher — Sun, 15 Mar 2020 07:00:39 +0000

Dr. Liji Thomas, MD via News-Medical Net – The US has witnessed a spate of patients presenting with acute lung injury associated with e-cigarettes or vaping product use. A new study published in the journal JAMA Internal Medicine shows the pattern of the outbreak in California where recreational cannabis use is legal and which has among the maximum cases of the strange illness. Vaping is the practice of using electronic or e-cigarettes, which has exploded into prominence among the younger generation in the US. The basic principle is the heating of the liquid within the device’s canister to produce an aerosol that is then inhaled. The fluids may contain one or more of a variety of ingredients, including nicotine, various cannabis constituents, flavorings, and other chemicals. The chief danger of vaping is the lack of regulation.From August 2019 to date, over 2,700 patients have been reported with e-cigarette, or vaping, associated lung injury (EVALI) in all the states of the US. The Study The investigators used data on 160 patients admitted in hospital with EVALI between August 7 and November 8, 2019. The patient data came from treating doctors who reported them to the local health department, which in turn transmitted the information to the California Department of Public Health. The data included epidemiologic and laboratory data on the patients, who underwent interviews based on a standard format. The questions assessed the types of vaping products used, how often they were used, and how the patients acquired them. The vaping products provided for investigation by some of the patients also underwent testing for active ingredients. The Results The investigators found that among 160 patients with EVALI of whom approximately 60% were male, with a median age of 27 years, about half received intensive care, and a little less than a third had to be put on mechanical ventilation. Four of them died in hospital. Of the 160 patients, 86 were subject to interview. Among this group, 83% said they vaped products containing tetrahydrocannabinol (THC), which is the psychoactive component of cannabis. 43% had vaped products containing cannabidiol (CBD), another principal constituent of the same plant. 47% had vaped products containing nicotine. Of the 87 products that showed only the presence of THC, over 90% were prefilled cartridges but only 48% of nicotine-only cartridges. Where did they get the products from? 75% of them had got their THC-containing vaping products from friends, unlicensed vendors, and other informal sources. 87 vaping products tested were obtained from only 24 of the 160 patients. The results showed that 56% had THC. 84% of this subset had vitamin E or vitamin E acetate, but none of the nicotine-containing subset. Flavorings were added to 56% and 76% of the THC- and nicotine-containing products, respectively. The median period from the last use of the vaping product to the onset of EVALI symptoms and hospital admission was 3 and 5 days, respectively. About 40% had smoked or were smoking conventional cigarettes as well. Common symptoms included cough, shortness of breath, and fever with chills, besides one or more gut symptoms. Laboratory criteria of intense inflammation were present. Implications The pattern of use of vaping product by type, as well as the clinical features of the patients, were broadly similar to the overall trends seen in other US states. It is noteworthy that though California permits the recreational use of cannabis by adults, most of the THC-containing products came from informal sources. The authors emphasize, “These findings underscore the importance for all clinicians, including outpatient health care providers, to consider EVALI in patients with a history of vaping who present with typical findings of infection, as well as monitor their clinical course and respiratory status closely for decompensation, in accordance with CDC guidance.” Secondly, more female than male patients seemed to require ICU admission, suggesting that females fare worse on exposure to tobacco smoke and other environmental toxins. Thirdly, depression, and anxiety are the most common illnesses found in patients with EVALI in California, which could indicate that such patients vape at higher rates or that such patients are at higher risk of EVALI. Again, vitamin E or vitamin E acetate proved to be present in most products containing THC. The study concludes, “The California Department of Public Health recommends that individuals refrain from using any vaping or e-cigarette products, particularly THC-containing products from informal sources, while this investigation is ongoing.” To read the original article click here.

The post Study looks at Lung Injury and Vaping THC and Vitamin E Acetate appeared first on Amazing Health Advances.

Best Practice Treatment Guidelines Help Doctors Identify and Treat Vaping-Associated Lung Injuries

AHA Publisher — Tue, 19 Nov 2019 08:00:54 +0000

Intermountain Medical Center via EurekAlert – As the outbreak of lung injuries and deaths associated with e-cigarettes, or vaping, continues to spread across the U.S., researchers at Intermountain Healthcare in Salt Lake City have effectively developed a best practice treatment guide to quickly identify and treat patients who develop the new and potentially fatal respiratory injury, according to a new study. “This is still an ongoing outbreak, and not something we’ve seen with vaping before,” said Denitza Blagev, MD, a pulmonary and critical care physician at Intermountain Healthcare, who is the lead author of a new study that outlines best practices for treatment for patients with e-cigarette or vaping-associated lung injury (E-VALI). The study is published in the November 8, 2019, issue of The Lancet, one of the world’s best-known and most prestigious peer-reviewed medical journals. The lung injury diagnosis and treatment guidelines developed by Intermountain Healthcare clinicians are based on the cumulative clinical experience of treating more than 60 patients throughout the health system’s 24 hospitals and 215 clinics. The Intermountain guidelines recommend shorter courses of moderate-dose steroids for patients who are either treated as outpatients, or admitted to hospitals, and higher doses of intravenous steroids that are tapered more slowly for patients who are critically ill on admission. Clinicians also recommend close outpatient follow-up, as complications after initial recovery are recognized. “Through sharing the guideline, we’re reaching clinicians and keeping e-cigarette or vaping-associated lung injury on everyone’s minds, especially as we enter flu season and diagnosing vaping associated lung injury becomes more challenging,” said Dr. Blagev. “We now have a standardized approach to treat these patients, and we’re starting to learn about what the recovery and complications are,” she added. “Time will show us the long-term outcomes and the cause of this new disease, but in the meantime, the surest way to prevent lung injuries associated with e-cigarettes, or vaping, is not to vape.” In the study, Intermountain Healthcare researchers identified 60 E-VALI patients at 13 different Intermountain hospitals or clinics in Utah from June 27, 2019, through October 4, 2019. The diagnosis was defined by a history of vaping or e-cigarette use within 90 days prior to symptoms, abnormalities shown in chest imaging, and no other cause for these findings (such as pneumonia). While the majority of E-VALI patients were admitted to an intensive care unit, many weren’t critically ill and recovered more quickly. These patients typically had flu-like symptoms, shortness of breath, cough, chest pain, and abdominal symptoms such as nausea, vomiting, and abdominal pain. Most patients with lung injuries associated with e-cigarettes or vaping were treated with antibiotics (due to overlapping pneumonia symptoms), oxygen, and steroids. While specific infectious disease testing was negative for all of the patients, most received antibiotics, researchers reported. The Intermountain clinicians attribute the clinical improvement of the patients’ health to the positive effect of the steroids they received. Most patients started to show improvement within days, researchers noted, however, six of the patients — or 10 percent of those enrolled in the study — relapsed and had complications that required hospital readmission. The majority of patients who were readmitted to the hospital had been critically ill when they initially came in for care, and half of them had resumed vaping after discharge, researchers reported in the Lancet study. In the first study to report follow-up findings for these patients, Intermountain clinicians performed a short follow-up exam after two weeks and found that, although most patients had improved significantly, many had residual abnormalities. Only 23 percent of the patients still needed supplementary oxygen, but most still showed some signs of lung abnormalities on their imaging and breathing tests. These findings are helping physicians recognize what lung injuries associated with e-cigarettes or vaping look like — and helping them maintain a high degree of suspicion when they diagnose lung injuries in patients who’ve been vaping. “Being vigilant about obtaining a patient’s vaping history when they’re admitted and keeping it in mind throughout their hospital stay, is essential,” said Dr. Blagev. “For some patients in our study, their vaping history didn’t emerge until they were well into the course of their disease.” While the majority of E-VALI patients vaped THC, some reported only vaping nicotine. Intermountain researchers reported no clear pattern emerged in terms of vaping device or the source of the vaping liquids among the patients. Patients in the study reported obtaining vaping e-liquids from local dealers or vape shops, friends, or social medial apps. Without a known cause of e-cigarette or vaping-associated lung injury, current recommendations are to avoid all e-cigarette or vaping exposure, Intermountain researchers advised in the study. According to the U.S. Centers for Disease Control and Prevention, 1,888 cases of e-cigarette or vaping-associated lung injury have been reported in the United States, including 37 deaths in 24 states. In Utah, 109 cases of E-VALI have been confirmed, with another seven cases under investigation in the state, as of Oct. 28. Dr. Blagev and her colleagues at Intermountain began to see E-VALI patients early last summer. The first case at Intermountain was recognized by pulmonologist Dixie Harris, MD, who, through her work in the Intermountain TeleHealth Critical Care service, noticed a cluster of patients seeking treatment at multiple Intermountain hospitals throughout Utah. The Intermountain TeleHealth Critical Care service is a systemwide proactive monitoring and response center where intensivist physicians and critical care nurses monitor data on large patient populations and provide clinical decision support remotely as bedside staff care for individual patients in hospitals throughout the Mountain West. The Intermountain TeleHealth Critical Care service allowed the rapid formation of a centralized task force, which enabled tracking and public reporting of cases, and sharing of clinical expertise among clinicians, according to the study. “The use of the TeleHealth Critical Care service allowed us to recognize the outbreak much earlier than if we had only relied on reports of separate cases in individual hospitals,” Dr. Blagev noted. To read the original article click here.

The post Best Practice Treatment Guidelines Help Doctors Identify and Treat Vaping-Associated Lung Injuries appeared first on Amazing Health Advances.